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Serum concentration and peritoneal transfer of aluminum during
treatment by continuous ambulatory peritoneal dialysis. The evolution of
the aluminum (Al) serum levels during a 2-year follow-up and the
peritoneal transfer of Al were studied in 22 patients treated by continu-
ous ambulatory peritoneal dialysis (CAPD), using a dialysate with a
very low Al concentration (r = 0.25 — 0.30 smoles/liter). Patients were
divided in three groups. A transfer of Al from the patient to the
dialysate was observed in all patients. In group I, patients exclusively
treated by CAPD and who have never received aluminum-containing
phosphate binders (ACPB), mean level (±sD) of serum Al stabilized
within a safe range (0.60 0.28 moles/liter). In group 2 the oral
administration of ACPB in patients exclusively treated by CAPD
induced a slow and progressive increase of Al serum concentration
despite the increase of the Al excretion through the peritoneal route. In
group 3, patients previously treated by hemodialysis and receiving
ACPB, the high serum Al levels observed before treatment by CAPD
decreased rapidly on CAPD. Al removal through the peritoneum was
higher in group 3 than in group 2 despite serum Al levels not statistically
different in both groups. Al removal through the peritoneum is mainly
influenced by serum and dialysate Al concentration. Al body stores
could play a role in the transfer of Al through the peritoneum. Three
cases of Al poisoning due to the accidental use of a dialysate with a high
Al content are reported.
Concentration serique et transfert a travers le peritoine de l'aluminium
au cours du traitement par Ia dialyse péritonéale continue ambulatoire.
L'évolution des taux sériques de l'aluminium (Al) durant 2 ans et le
transfert de l'Al a travers le peritoine ont été étudiés chez 22 patients
traités par Ia dialyse péritonéale continue ambulatoire (DPCA) en
utilisant un dialysat dont Ia teneur en Al était particulièrement basse
(écarts 0,25 — 0,30 moles/litre). Les patients ont eté répartis en trois
groupes. Un transfert d'aluminium du patient vers Ic dialysat a ete
observe dans tous les cas. Dans le groupe I, patients uniquement traités
par DPCA et qui n'ontjamais recu de gels d'Al, les taux moyens (± I
SD) d'Al sérique se stabilisent dans une zone dite de sécunté (0,60
0,28 zmoles/Iitre). Dans Ic groupe 2, l'administration orale de gels d'Al
chez des patients exclusivement traitCs par DPCA entraine une aug-
mentation lente et régulière des taux sCriques d'Al, en dépit d'une
augmentation des eliminations d'Al a travers le péritoine. Dans le
groupe 3, patients d'abord traités par hémodialyse et recevant des gels
d'Al, les taux élevés d'Al observes avant le traitement par DPCA
diminuent rapidement sous traitement par DPCA. La soustraction d'Al
a travers Ic peritoine est plus élevée dans le groupe 3 par rapport au
groupe 2, en dépit de taux seriques qui ne sont pas statistiquement
diffCrents dans les deux groupes. La soustraction d'Al a travers le
péritoine depend principalement de Ia concentration du serum et du
dialysat en Al. Les stocks cellulaires d'Aljouent peut-etre un role dans
Ic transfert de l'Al a travers le péritoine. Trois observations d'intoxica-
tion par l'aluminium, dues a l'usage d'un dialysat ayant pour des raisons
accidentelles, une forte teneur en Al, sont rapportees.
919
A positive aluminum (Al) balance is considered a causative
agent or a contributing factor of some complications observed
among patients with endstage renal disease (ESRD), as the
dialysis encephalopathy syndrome [1, 2], renal osteodystrophy
[3, 4], and anemia [5]. Al intoxication among dialyzed patients
has mainly been reported in patients on maintenance hemodial-
ysis (HD). The extra sources of Al in such patients are high Al
dialysate concentration and/or the consumption of aluminum-
containing phosphate binders (ACPB) [6—10]. Evolution of
serum Al concentration in patients undergoing continuous
ambulatory peritoneal dialysis (CAPD) remains controversial
[11—15]. A multicentric acute and severe Al intoxication in
relation to a contamination of the dialysate illustrates the
possibility of massive Al loading through the peritoneal route
[16]. On the contrary Al removal through the dialysate has been
demonstrated using fluid with very low Al content [17]. This
study was conducted to investigate further the peritoneal trans-
fer of aluminum in patients treated by CAPD under different
conditions.
Methods
Patients. Fifty normal healthy subjects of both sexes who
were not taking ACPB served as control subjects for Al serum
concentration. Twenty-two patients (13 males, 9 females) were
studied after we received informed consent. Mean age (±sD) at
the beginning of CAPD was 56.04 13.44 years (range, 32 to
81). Primary renal disease exhibited in the patients was glomer-
ulonephritis in eight, diabetic nephropathy in seven, chronic
interstitial pyelonephritis in five, and nephropathy of unknown
origin in two.
The patients were divided in three groups (Table 1): Group I
included nine patients who before the study had been treated by
CAPD exclusively during a mean period of 13.3 7.4 months
and had never received ACPB. Group 2 included seven patients
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Table 1. Patient characteristics
DN 4
CIN 2
6 M 53.3 12.1 GNC I
9 3 F (32—75) UN2
DN 2
3 M 59.7 15.2 CIN 3
2 7 4F (32—81) GNC2
4M 55.8±12 GNC5
3 6 2F (37—74) DN I
Duration of treatment Duration of previous Intake during
Primary renal by CAPD before the study treatment on hemodialysis CAPD treatment
diseaseb months months Al, mg/day
13.3 7.4
(3 — 27)
10
(1 — 19) 863 428
3 4.1 75.8 38.9
(1— 12) (27— 144) 791 750
The values are mean SD.
Abbreviations for primary renal disease are: GNC, glomerulonephritis: DN, diabetic nephropathy; CIN, chronic interstitial nephritis; UN,
nephropathy of unknown origin.
also treated exclusively by CAPD during a mean period of 10
5.6 months but who received ACPB to control serum phos-
phate. Group 3 included six patients previously treated by
hemodialysis for a mean period of 75.8 38.9 months (two
were on home dialysis treatment) and who received ACPB
during treatment by hemodialysis and CAPD. These patients
had been transferred from HD therapy to CAPD because of
cardiovascular instability in three patients, vascular access
problems in one, and personal choice in two. The duration of
treatment by CAPD before the study was different in the three
groups (Table 1).
The Al compound used to control serum phosphate during
CAPD treatment was exclusively Al hydroxide in capsules [1 g
Al(OH) 3 = 346 mg or 12.7 mmoles of Al].
We also observed three patients intoxicated during 90 days
by using a commercial dialysate that unintentionally contained
a very high Al concentration (53 to 57 moles/liter).
Aluminum investigations
Methods of measurement of aluminum. Measurements of Al
in serum, urine, dialysis fluid, and peritoneal drainage fluids
were performed by electrothermal atomic absorption spectrom-
etry using an atomic absorption spectrophotometer (Model 370,
Perkin Elmer, Norwalk, Connecticut) equipped with a graphite
furnace (HGA 74), an autosampler AS 1, and an aluminum
hollow-cathod lamp (309.2 nm) [18, 191. For serum and urine,
the program consisted of the following: dry step (50 sec
increasing to 350°C, 50 sec at 350°C), char step (45 sec increas-
ing to 1400°C, 5 sec at 1400°C), and atomize step (5 sec at
2700°C). For dialysis and peritoneal drainage fluids, the pro-
gram consisted of the following: dry step (40 sec increasing to
350°C, 20 sec at 350°C), char step (45 sec increasing to 1400°C, 5
sec at 1400°C), and atomize step (5 sec at 2700°C). During the
atomize cycle the argon gas purge was stopped to allow more
sensitive measurements. Aluminum content of the three com-
mercial dialysates routinely used in our unit was determined in
56 randomly selected 2-liter 1.5% dextrose bags belonging to
the batches used during protocol. The content of high concen-
tration dextrose solutions was determined in six randomly
selected bags after completion of the study. Blood samples
were collected through a plastic cannula and the serum was
immediately separated. Blood urine and drainage fluid samples
were stored at 4°C immediately after collection and measure-
ments were made on the next day.
Twenty microliters of each sample were injected directly with
a nontouching technique into the graphite tube [19]. Analysis
was done in duplicate. The coefficient of variation with this
method was 3%. The detection limit was 0.15 iimoles/liter.
Aluminum measurements. The 22 patients investigated for
peritoneal transfer were submitted from the beginning of CAPD
treatment to serial determinations of Al serum concentration at
least every 6 months. Al food intake and Al contained in stools
were never measured and Al balance studies were not
performed.
Peritoneal mass transfer protocol. Studies were performed
during a 24-hr period three times at 3-month intervals (studies
A, B, and C). During the 6-month period required for the study,
the patients were on a four-bag exchange schedule including
three bags with a 1.5% dextrose concentration and one bag with
a concentration between 3.8 and 4.5%. Aluminum peritoneal
transfer equals the daily inflow volume in liters multiplied by
dialysate aluminum concentration minus the daily outflow
volume multiplied by drainage aluminum concentration. The
mass transfer is positive when a gain is observed and it is
negative when there is a removal. The residual renal clearance
corrected for body surface and the peritoneal clearance of
creatinine were calculated as previously described [20] using a
multiparameters analyzer (SMAC Techicon, Technicon Instru-
ments Corporation, Tarrytown, New York). Proteins in plasma
were measured using the biuret method. The proteins in urine
and drainage fluid were determined using the sulphosalicyclic
acid method.
Aluminum oral loading protocol. In seven group 1 patients,
the aluminum peritoneal mass transfer was determined at the
end of the 6-month study period, after an aluminum intake of 4
g/day of aluminum hydroxide (1.4 g or 51 mmoles/Al) during 6
days.
Results
Serum creatinine, plasma proteins, and peritoneal protein
losses. Results are summarized in Table 2. Significant statistical
differences were observed between the different groups, but no
significant variations were observed in each group during the
study period. Total serum proteins and serum albumin were
lower while protein losses through the dialysate out flow were
higher in group 1 than in groups 2 and 3.
Peritoneal and renal clearances. Mean peritoneal creatinine
clearance was between 4.3 and 4.8 mI/mm, without a significant
Number of
Groups patients Patients
Mean age
(range)
years
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Table 2. Biological parameters, peritoneal and renal residual creatinine clearance?
Serum Protein losses
Number creatinine Serum Serum in drainage Peritoneal creat. Residual renal
of p,moles/ proteins albumin fluid clearance creat. clearance
Groups patients Study liter gluier giliter g/24 hr mi/mm mi/mm
9 A 886 193 57.1 6 30 4 7.9 2.7 4.6 0.9 3.2 2.5
I 9 B 860 178 58.4 5.8 30 4 8.3 3.8 4.7 1.0 3.0 2.1
9 C
D'
938 231
890 200c
58.4 4.5
58.0 5c.d
31 3
30 6 9.2 2.28.4 35C.1 4.8 1.047 10g 2.7 2.03.0 2.lca
7 A 1049 398 64.7 3.9 33 4 4.6 1.4 4.5 0.4 1.8 2.4
2 7 B 978 357 68.0 5.9 35.5 5 5.2 2.2 4.8 0.7 1.9 2.6
6 C
D"
1013 387
1013 360 66.3 3.4660 + 6 5df
36 4
34 4g
6.1 2.3
5.7
4.8 0.7
4.6 06g
1.1 2.4
1.6 2.2a1
6 A 1096 96 62.8 5.2 31 3 4.0 1.5 4.3 1.2 0.23 0.52
3 6 B 1162 105 66.0 3.3 33 3 4.6 1.4 4.3 1.0 0.18 0.36
5 C
D"
1160 143
1130 120c.f
63.6 7.464.0 4.5 32 332 3 5.2 1.04.8 4.6 1.14.2 10g 0.09 0.200.16 O.3O
a All values are expressed as mean SD.
b These values represent the mean of the three studies.
Group I versus group 3, P < 0.01.
d Group I versus group 2, P < 0.01.
Group I versus group 2, NS.
Group 2 versus group 3, NS.
Group I versus groups 2 and 3, NS.
difference between the three groups. Residual renal creatinine
clearance in group 1 was stable around 3 mI/mm during the
study period. Creatinine clearances were lower in group 2 than
in group 1, despite a shorter duration of treatment by CAPD
(Table 1), but differences were not statistically significant.
Residual renal function in group 3 was in most cases negligible
and always below 1 mI/mm.
Evolution of Al serum levels. The mean serum Al level of the
normal control group was 0.34 0.08 moles/1iter (range, 0.18
to 0.48 imo1es/liter). The evolution of the serum Al levels of the
patients during the first 2 years of treatment by CAPD is shown
in Figure 1. In group 1, the mean values increased slowly during
the first months and stabilized after 1 year around a mean value
of 0.51 0.19 mo1es/1iters slightly over the concentration of
the control group. In group 2, we observed a progressive
increase of serum Al concentration from 0.70 0.30 moles/
liter at the start of treatment by CAPD to 1.88 0.46
moles/liter at 1 year reaching a plateau until the end of the
second year. In group 3 the patients previously treated by
hemodialysis and receiving ACPB have high serum Al values,
3.92 0.84 moles/liter, at the start of treatment by CAPD. A
progressive decrease more rapid during the first 6 months is
observed during CAPD treatment. At the end of the second
year of treatment by CAPD, Al serum concentrations remained
high, 2.10 1,0 smoles/liter.
Peritoneal mass transfer
The Al serum concentration. During the 6-month period of
the peritoneal transfer study, the Al serum concentration of the
three groups remained stable. Mean Al serum levels of group I
were much lower, 0.60 0.28 moles/liter, than in groups 2 and
3, respectively, 2.08 0.80 and 2.39 0.77 moles/1iter. Mean
values of groups 2 and 3 were not statistically different (Table
3),
Dialysate. The Al content of the dialysate of the three brands
we routinely use in the department were similar (Table 4). The
mean Al content of the 1.5% dextrose concentration was 0.27
3.
Q.)
Q)0
E
2-
0J
o 6 12 18 24
Time, months
Fig. 1. Evolution ofAl serum level (moles/liter) during the first 2 years
of CA PD treatment. Patient groups are as follows: group I (—U),
patients exclusively treated by CAPD and who have never received
ACPB; group 2 (0—0), patients exclusively treated by CAPD and
receiving ACPB; group 3 (I •), patients previously treated by
hemodialysis and receiving ACPB. The shaded area represents the
normal range.
0.07 moles/liter. The mean Al content of the high dextrose
concentration was 0.29 0.09 imoles/liter.
Drainage fluid. The Al content of the drainage fluid of each
4 6
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Number of Serum
Drainage
fluid
Group Study patients pinoles//iter /2moleslliter
A
B
C
Db
9
9
9
0.61 0.31
0.52 0.13
0.67 0.33
0.60 028c,d
0.32 0.09
0.34 0.07
0.31 0.04
0.33 00,d
2 A
B
C
Dh
7
7
6
1.95 0.76
2.07 0.61
2.22 1.00
2.08 080d,e
0.47 0.10
0.44 0.10
0.51 0.09
0.47 010d.f
3 A
B
C
D5
6
6
5
2.11 0.94
2.56 0.53
2.50 0.45
2.40 0.78
0.84 0.19
0.80 0.14
1.03 0.25
0.89 0.19cf
All values are expressed as mean SD.
These values represent the mean of the three studies.
Group I versus group 3, P < 0.01.
d Group I versus group 2, P < 0.01.
Group 2 versus group 3, NS.
Group 2 versus group 3, P < 0.01.
group was statistically different. The concentrations remained
stable during the study period in groups I and 2 and increased in
group 3 reaching 1.03 0.25 imoles/liter at the end of the study
(Table 3). The aluminum concentration of the dialysate outflow
was always higher than the aluminum concentration of the
dialysate inflow and lower than the serum concentration (Table
3). Such results illustrate a transfer of Al from the body fluids
into the dialysate. There is a statistical correlation between the
Al serum concentration and the Al drainage fluid concentration
(r 0.518, P < 0.01).
Through the peritoneum. The daily Al removal through the
peritoneum was very low (0.50 0.50 imoles/24 hr) in group 1
and much higher in the two other groups (Table 5). The values
in group 3 (5.46 2.49 moles/24 hr) were higher than in group
2 (2.00 1.16 moles/24 hr) although the differences between
the serum Al concentration of groups 2 and 3 were not
statistically different (Table 3).
The aluminum renal excretion. Renal excretion was low in
groups 1 and 2 and almost negligible in group 3 (Table 5). Al
urine concentrations were statistically correlated to the residual
renal function expressed by the creatinine clearance (r = 0.438,
P < 0.004).
The effect ofaluminum oral loading. The daily oral intake of
1.4 g (51 mmoles) of Al per day during 6 days induced a rapid
increase of serum Al concentration in seven group I patients
despite a fourfold increase of Al excretion through the peritone-
al route (Table 6).
The evolution after the Al poisoning. The intoxication was
detected in two symptom-free patients because of routine
serum Al measurement and in one patient because of a general
malaise with anorexia, nausea, and cramp-like abdominal pain.
Al serum levels measured before the intoxication in two out of
the three patients were 0.5 and 0.7 moles/liter. Al serum levels
when the intoxication was suspected were 18, 21, and 23
molesfliter, respectively. Following treatment by continuous
peritoneal dialysis with a fluid containing Al concentration
Value (mean SD)
Origin Number of bags tested pinolesiliter
Assistance Publiqueb
1.5% Dextrose 26
4.5% Dextrose 2
Travenol Dianealc
1.5% Dextrose
3.86% Dextrose
Dialysate solutions are from:
a Lyon, Franceb Paris, France
Deerfield, Illinois
below 0.5 moles/liter, the serum Al levels decreased gradual-
ly. Nevertheless, two patients died within a month, one from
dementia, the second from gastrointestinal bleeding. The third
patient is still being treated by CAPD; his serum Al level 20
months after the acute intoxication was 1 mole/liter.
Discussion
As for a dialysis membrane [21, 22] transfer of Al across the
peritoneum was mainly determined by the concentration gradi-
ent between the free diffusible part of Al in the serum and the
dialysate. For such a reason the amount of Al removed through
the peritoneal route from patients treated by peritoneal dialysis
will rely mainly on plasma aluminum concentration. A negative
aluminum transfer requires dialysate Al concentration below
the free diffusible plasma Al concentration estimated to be
around 20 to 40% of total plasma Al [12, 22, 23]. The possibility
of a reverse situation with a positive Al transfer is well
illustrated by the recently reported severe acute Al intoxication
[16] occurring in patients treated by CAPD using a dialysate
with a very high Al concentration. Our three observations, with
two deaths, illustrate the severity of such acute Al poisoning.
Serum Al concentration relies on different factors as the Al
exposure before and during the dialysis including the Al con-
centration of the dialysate, the consumption of ACPB, the
endogenous loss of aluminum through the gastrointestinal tract
and the residual renal function. The multiple factors involved in
Al loading and Al removal through various routes can easily
explain the large variation observed among the Al serum levels
of patients treated by CAPD [11—13, 15].
In group I patients exclusively treated by CAPD and who
have never received ACPB, serum Al values remained very low
(0.60 0.28 imoles/liter). Nevertheless, the mean Al concen-
tration of the dialysate outflow in the three studies was slightly
superior to the average Al concentration of the 1.5% dextrose
concentration dialysate inflow suggesting a very small negative
transfer. Al concentration in the outflow equaled about 50% of
the serum Al concentration values higher (Table 3) than the
usually estimated 20 to 40% of free diffusible fraction. Different
factors can explain such surprising results. The low serum
protein levels around 58 g/liter observed in this group (Table 2)
can contribute to increase the free diffusible fraction of serum
Table 3. Aluminum concentration of serum and drainage fluid during
the study period
Table 4. Aluminum concentration of the dialysate solutions
Aguettant
1.5% Dextrose 12
4.0% Dextrose 2
0.25 0.04
0.28 0.07
0.26 0.07
0.28 0.09
0.29 0.09
0.31 0.09
18
2
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Table 5. Aluminum removal through urine and drainage fluid, jj.molesI24 hrC
Group Route of removal
StudyA StudyB StudyC
Removal
Mean of three studies
(9) (9) (9)
Urine 0.51 0.71 0.30 0.22 0.33 0.29 0.38 0.47
I Drainage fluid
Total
0.43 0.4
0.95 0.77
0.70 0.67
1.0 0.7
0.37 0.25
0.7 0.37
0.50 0.50
0.88
Urine
(7)
0.44 0.62
(7)
0.45 0.58
(6)
0.18 0.29 0.37 0.54
2 Drainage fluid 1.93 0.88 1.66 1.07 2.46 1.37 2.00 1.16
Total 2.38 1.15 2.12 1.27 2.65 1.24 2.37 1•24bc
Urine
(6)
0.10 0.37
(6)
0.10 0.2
(5)
0 0.10 0.27
3 Drainage fluid 4.96 2.13 4.84 1.79 7.48 1.77 5.46 2.49
Total 5.13 2.14 4.94 1.68 7.48 1.77 5.56 2.l5C
All values are expressed as mean so; the number of patients is in parentheses.
b Group I versus group 2, P < 0.01.
Group 2 versus group 3, P < 0.01.
d Group I versus group 3, P < 0.01.
Al. The high peritoneal protein losses observed in this group
allowed removal through the drainage fluid of Al fixed on
proteins. Finally, as for other molecules, diffusion should not be
considered as the only mechanism involved in peritoneal trans-
fer. A sieving effect in relation to the transperitoneal ultrafiltra-
tion process can also apply to aluminum and explain Al
concentration in the outflow higher than expected from diffu-
sion alone [24].
In group 1 which was never exposed to extra sources of
aluminum, the mean daily aluminum removal including the
urine and the peritoneal routes reached 0.88 0.66 jimoles/day,
a value slightly superior to the daily urine excretion, 0.6 0.3
moles/day, found by Kaehny, Hegg, and Alfrey [25] in normal
subjects. Such Al removal contributes to the stabilization of Al
serum concentration around values considered to be safe [8, 13]
although higher than the control (see Fig. I). In this group Al
renal excretion was almost equal to Al removal through the
drainage fluid which illustrates the beneficial effect of a persist-
ing residual renal function during the first year of treatment by
CAPD [20].
The oral administration of ACPB to patients treated by
CAPD induced an increase of Al serum concentration despite
the large increase of the Al excretion through the peritoneum
and likely the intestinal route. This was observed both in group
I patients receiving an aluminum load during 6 days and in
group 2 patients during a 6-month period. We do not know if an
equilibrium between the Al intake from various sources includ-
ing ACPB and the peritoneal aluminum removal will be ob-
tained and if serum Al concentration will stabilize for a very
long period.
In group 3 patients previously treated by hemodialysis and
receiving ACPB, the evolution of the Al serum level is the
opposite of that which was observed in group 2. The high serum
Al concentrations decreased rapidly during the first months of
treatment by CAPD and more slowly later (see Fig. 1). The Al
concentration in the drainage fluid and the Al removal through
the peritoneal route were much higher in group 3 than in group 2
(Table 5). A higher Al cell content in group 3 in relation with a
long standing Al exposure is likely. The exact reason of such a
Table 6. Aluminum loading experiment in patients of group I. Oral
administration of 4 g/day of aluminum hydroxide during 6 days (51
mmoles of Al/day)a
.Serum aluminum
jsmoles/liter
DayO Day6
0.61 0.34 P < 0.05 1.2 0.34
Aluminum removal
Urine, molesI24 hr 0.37 0.27 NS 0.80 0.77
Drainage fluid, j.tmolesl
24 hr 0.31 0.22 P < 0.01 1.31 0.84
Total, molesI24 hr 0.69 0.27 P < 0.01 2.16 1.00
a All values are expressed as mean SD.
situation remains unclear. One can expect that the Al cell
content in group 3 is higher than in group 2, because of a longer
Al exposure. For this reason, more rapid transfer from the body
cells into the plasma and from the plasma into the peritoneum
without a significant change in serum aluminum values can be
observed during the dialysis procedure. Accurate kinetic stud-
ies with serial serum Al determinations during the dialysis
process and after stopping the dialysis could perhaps clarify this
unexpected situation.
Our results agree with the recent data reported by Gokal et al
[13] who have also observed in a few patients treated by CAPD
a decrease in serum Al levels when serum values were high at
the start of treatment and a moderate increase in patients not
receiving ACPB and with normal serum levels at the beginning
of CAPD treatment.
Much attention should be paid to the Al concentration of the
dialysate used for peritoneal dialysis either intermittent or
continuous to avoid positive peritoneal transfer and chronic
aluminum loading from the dialysate of patients with low serum
Al values. Our data suggest that an Al content of the dialysate
below 0.30 moles/liter can be considered as safe. Such Al
concentrations are lower than those of the dialysate used by
Sorkin et al [17] and Gokal et al [13] to treat patients on CAPD.
The level of the dialysate and the serum are not the only factors
which can interfere with the aluminum transfer across the
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peritoneal membrane. Gacek et al [26] demonstrated that slight
fluctuation in dialysate pH can cause dramatic changes in
aluminum dialyzability through artificial membranes. This
could also be, as suggested by Gilli et at [271, an important
factor playing a role in transfer through the peritoneum. The
usual pH between 5.5 and 6 of commercial available solutions
can favor a positive transfer across the peritoneum.
In conclusion, in patients treated by CAPD positive or
negative transfer of Al through the peritoneum were observed
in relation to the Al levels of the dialysate and the serum and
perhaps to the Al cell concentration. Despite very low Al
concentration in the dialysate, the patients were at risk of an
increase of serum Al concentration as soon as they took ACPB.
Regular control of serum Al levels in such patients was justified
even if serum Al did not reflect the aluminum store [28, 29] in
uremic patients. In patients with high serum levels large
amounts of Al can be removed through the peritoneal route.
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